The company has not filed an annual or quarterly report since its Q1 FY2021 10-Q, filed May 10, 2021. Its latest SEC filing is a 15-12B from Jul 26, 2021.
10-Q for Q1 FY2021, filed May 10, 2021
The sections below describe the company as of the FY2020 annual report.
Develops small-molecule drug candidates targeting gene regulation for cancer patients, including people with blood cancers and solid tumors.
10-K for FY2020, filed Feb 24, 2021We are a clinical-stage biopharmaceutical company using our expertise in epigenetics to discover and develop novel therapeutics that…View ↗
We have utilized our epigenetics platform to discover and design our wholly owned product candidates, pelabresib (CPI-0610) and CPI-0209.…View ↗
We have a preclinical pipeline of compounds that target the microenvironment of solid tumors and hematological malignancies, as well as…View ↗
No revenue was reported.
10-K for FY2018, filed Mar 14, 2019
10-Q for Q1 FY2021, filed May 10, 2021
−$40.1MView ↗
8-K, filed Jul 15, 2021
The aggregate consideration paid by Purchaser to acquire the Shares in the Offer and Merger, and settle the Constellation stock options in…View ↗
8-K, filed Jun 2, 2021
Planegg/Munich, Germany and Cambridge, Mass. – June 2, 2021 – MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation…View ↗
Competes with Incyte, Bristol-Myers Squibb, CTI Biopharma, Nippon Shinyaku, Sierra Oncology, Geron, Imago BioSciences, MEI Pharma, Helsinn, AbbVie, GlaxoSmithKline, Boehringer Ingelheim, TG Therapeutics, Nuvation Bio, Zenith Epigenetics, Epizyme, Daiichi Sankyo, Jiangsu Hengrui Medicine, Pfizer, and Ascentage Pharma
10-K for FY2020, filed Feb 24, 2021Ruxolitinib, a JAK inhibitor developed and marketed by Incyte, was approved by the FDA in 2011 as a first-line treatment for intermediate-…View ↗
Loading...
